Date: 2012-01-12
Type of information: Grant
Company: Cell Medica (UK)
Investors: Technology Strategy Board (UK)
Amount:
Funding type: grant
Planned used: Cell Medica, a UK cellular therapeutics company that develops, manufactures and provides cellular immunotherapy products for the treatment of infectious disease and cancer, has received notice of grant funding from the Technology Strategy Board for a Phase I/II clinical trial - ASPIRE (Adenovirus-Specific Paediatric Immune Reconstitution) in collaboration with the UCL Institute of Child Health / Great Ormond Street Hospital for Children NHS Trust.
Others: The ASPIRe study is designed to demonstrate the safety and efficacy of Cytovir ADV - Cell Medica’s adoptive cellular therapy for the treatment of adenovirus infections in paediatric patients following bone marrow transplant (allogeneic haematopoietic stem cell transplant or allo-HSCT).
Adenovirus infections cause mortality in up to 30% of children in high risk patient populations following allo-HSCT and current antiviral drug therapies are of limited benefit. Adoptive cellular therapy has already shown promising results in preventing viral disease in patients receiving a bone marrow transplant 1, 2.
Cell Medica will be study sponsor and will prepare their adenovirus specific T cell therapy products (Cytovir ADV) for patients being treated. Dr Waseem Qasim and Prof Bobby Gaspar of the UCLInstitute of Child Health / Great Ormond Street Hospital for Children NHS Trust are the study investigators.
Therapeutic area: Cancer - Oncology - Infectious diseases
